Vytorin/Zetia Drug Marketing
Result: $41.5 million settlement
In re Vytorin/Zetia Marketing, Sales Practices & Products Liability Litigation
Lieff Cabraser served on the Executive Committee of Plaintiffs’ Steering Committee in multidistrict litigation arising out of the sale and marketing of Vytorin and Zetia, two cholesterol drugs marketed and sold by Merck/Schering-Plough Pharmaceuticals, a joint venture between Merck & Co., Inc. and Schering-Plough Corp.
Plaintiffs alleged that Vytorin and Zetia were marketed as being more effective than other anti-cholesterol drugs and were sold at higher prices when they were no more effective than less expensive anti-cholesterol drugs.
On February 9, 2010, the Court granted final approval to a $41.5 million settlement for persons and entities which paid for these drugs between November 2002 and the date of final approval of the settlement.
Civil Litigation News
Judge Will Grant Preliminary Approval to $255M Economic Loss Settlement Against Juul
As reported by Law360, on January 20, 2023, U.S. District Judge William H. Orrick of the Federal District Court for the Northern District
Consumer Class Action Over Evenflo Child Car Seats to Move Forward
On Wednesday, January 3, 2023, The 1st Circuit Court of Appeal in Boston declined to rehear its November 23rd decision reviving the
Federal Court says Evenflo must face ‘Big Kid’ booster seat safety litigation
The 1st Circuit Court of Appeal in Boston has revived class action litigation accusing Evenflo Company Inc of misleading consumers about the